Catalent Pharma Solutions, has begun to expand its highly potent and cytotoxic clinical drug packaging capabilities within its 450,000- square foot campus in Kansas City, Missouri.

The expansion will increase the available packaging space for highly potent compounds adding two large packaging suites, a sampling lab, and space for various storage conditions. Segregated and separated from non-potent manufacturing operations, the new 6,000-square foot facility is capable of handling SafeBridge Category 3, 4 and cytotoxic compounds. Completion is expected in January 2015.

Catalent already has several highly potent and cytotoxic drug packaging suites in its clinical supply facility in Bolton, UK, providing end-to-end clinical supply solutions from clinical supply management, comparator sourcing, and primary packaging to storage and distribution globally.

Catalent's Kansas City campus provides a range of fully integrated support services, from formulation development and small and large molecule analytical testing, to clinical and commercial-scale manufacturing and packaging of a variety of oral solid dose forms.

Source: Catalent